

Resource Summary Report

Generated by [RRID](#) on Aug 27, 2026

HCC364

RRID:CVCL_5134

Type: Cell Line

Proper Citation

RRID:CVCL_5134

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_5134

Proper Citation: RRID:CVCL_5134

Description: Cell line HCC364 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Lung adenocarcinoma

Defining Citation: [PMID:25485619](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:28196595](#), [PMID:29681454](#), [PMID:30894373](#), [PMID:31068700](#), [PMID:31803961](#)

Comments: Miscellaneous: Direct author submission of STR profile from Girard, Luc & Gazdar, Adi F., Population: Caucasian., Part of: MD Anderson Cell Lines Project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: HCC364

Synonyms: HCC0364, HCC-364, Hamon Cancer Center 364

Cross References: EFO:EFO_0006420, ArrayExpress:E-MTAB-2706, BioGRID_ORCS_Cell_line:231, BioSample:SAMN03473003, BioSample:SAMN10988412, cancercellines:CVCL_5134, Cell_Model_Passport:SIDM01597, Cosmic:903630, Cosmic:1146934, Cosmic:1209733, Cosmic:2472917, DepMap:ACH-000575, EGA:EGAS00001000610, GEO:GSM434285, GEO:GSM794378, GEO:GSM817113, IGRhCellID:HCC364GEO, PharmacDB:HCC364_499_2019, Progenetix:CVCL_5134, Wikidata:Q54881707

ID: CVCL_5134

Record Creation Time: 20220427T220319+0000

Record Last Update: 20260815T233705+0000

Ratings and Alerts

No rating or validation information has been found for HCC364.

No alerts have been found for HCC364.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 5 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Gracilla DE, et al. (2026) FET Fusion Oncoproteins Disrupt Physiologic DNA Repair and Create a Targetable Opportunity for ATR Inhibitor Therapy. Cancer research, 86(11), 2660.

Pulice JL, et al. (2025) Amplified dosage of the NKX2-1 lineage transcription factor controls its oncogenic role in lung adenocarcinoma. Molecular cell, 85(7), 1311.

Nokin MJ, et al. (2024) In?vivo vulnerabilities to GPX4 and HDAC inhibitors in drug-persistent versus drug-resistant BRAFV600E lung adenocarcinoma. Cell reports. Medicine, 5(8), 101663.

Kim JW, et al. (2022) Capicua suppresses YAP1 to limit tumorigenesis and maintain drug sensitivity in human cancer. Cell reports, 41(1), 111443.

Kofink C, et al. (2022) A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo. Nature communications, 13(1), 5969.